Key clinical point: Quitting smoking prior to a lung cancer diagnosis is associated with a significant survival benefit, even among patients who recently stopped smoking.
Major finding: The risk of death from any cause was cut by 12% for lung cancer patients who quit smoking up to 2 years before diagnosis, 16% for patients who quit 2-5 years before diagnosis, and 20% for those who quit more than 5 years before diagnosis.
Study details: A pooled analysis of 35,481 patients with lung cancer enrolled in 17 studies conducted by the International Lung Cancer Consortium.
Disclosures: The studies had multiple supporters. Dr. Fares reported no relevant disclosures, but one researcher disclosed relationships with AbbVie, AstraZeneca, MedImmune, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche Canada, and Takeda.
Fares AF et al. ASCO 2020, Abstract 1512.